Skip to main content

Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study.

Publication ,  Journal Article
Yang, ES; Halabi, S; Rothe, M; Garrett-Mayer, E; Mangat, PK; Pisick, E; Dib, E; Burgess, EF; Zakem, M; Rohatgi, N; Bilen, MA; O'Lone, R ...
Published in: JCO Precis Oncol
February 2023

PURPOSE: The TAPUR Study is a phase II basket trial that aims to evaluate activity of approved targeted agents in patients with advanced cancers with potentially actionable genomic variants. Data from a cohort of patients with metastatic castrate-resistant prostate cancer (mCRPC) and BRCA1/2 mutations treated with olaparib are reported. METHODS: Eligible patients with measurable mCRPC were matched to treatment according to protocol-specified genomic matching rules. Patients had no remaining standard treatment options, Eastern Cooperative Oncology Group performance status 0-2, and adequate organ function. Simon's two-stage design was used with a primary end point of disease control, defined as objective response or stable disease of at least 16-week duration. Secondary end points include radiographic progression-free survival, overall survival, duration of response, duration of stable disease, and safety. RESULTS: Thirty patients with mCRPC with BRCA1/2 mutations were treated with olaparib. The disease control rate was 69% (95% CI, 51 to 81), and the objective response rate was 58% (95% CI, 37 to 77). The median radiographic progression-free survival and the median overall survival were 38.4 (95% CI, 16.3 to 52.1) weeks and 76.4 (95% CI, 49.3 to 106.0) weeks, respectively. Six of 30 (20%) patients experienced grade 3-4 adverse or serious adverse events including anemia, aspiration, decreased WBC count, and fatigue. CONCLUSION: Olaparib has antitumor activity in patients with mCRPC with BRCA1/2 mutations and warrants further study to determine how to best integrate it into the standard treatment of patients with BRCA1/2-mutated prostate cancer.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

JCO Precis Oncol

DOI

EISSN

2473-4284

Publication Date

February 2023

Volume

7

Start / End Page

e2200505

Location

United States

Related Subject Headings

  • Prostatic Neoplasms, Castration-Resistant
  • Phthalazines
  • Mutation
  • Male
  • Humans
  • BRCA1 Protein
  • Antineoplastic Agents
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Yang, E. S., Halabi, S., Rothe, M., Garrett-Mayer, E., Mangat, P. K., Pisick, E., … Schilsky, R. L. (2023). Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study. JCO Precis Oncol, 7, e2200505. https://doi.org/10.1200/PO.22.00505
Yang, Eddy S., Susan Halabi, Michael Rothe, Elizabeth Garrett-Mayer, Pam K. Mangat, Evan Pisick, Elie Dib, et al. “Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study.JCO Precis Oncol 7 (February 2023): e2200505. https://doi.org/10.1200/PO.22.00505.
Yang ES, Halabi S, Rothe M, Garrett-Mayer E, Mangat PK, Pisick E, et al. Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study. JCO Precis Oncol. 2023 Feb;7:e2200505.
Yang, Eddy S., et al. “Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study.JCO Precis Oncol, vol. 7, Feb. 2023, p. e2200505. Pubmed, doi:10.1200/PO.22.00505.
Yang ES, Halabi S, Rothe M, Garrett-Mayer E, Mangat PK, Pisick E, Dib E, Burgess EF, Zakem M, Rohatgi N, Bilen MA, O’Lone R, Grantham GN, Schilsky RL. Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study. JCO Precis Oncol. 2023 Feb;7:e2200505.

Published In

JCO Precis Oncol

DOI

EISSN

2473-4284

Publication Date

February 2023

Volume

7

Start / End Page

e2200505

Location

United States

Related Subject Headings

  • Prostatic Neoplasms, Castration-Resistant
  • Phthalazines
  • Mutation
  • Male
  • Humans
  • BRCA1 Protein
  • Antineoplastic Agents
  • 3211 Oncology and carcinogenesis